-
Lindsey E. Jones et al. Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma. Neuro-Oncology Advances, 2020. We established robust, versatile, and well-characterized Patient Derived Cells (PDC) of an IDH1-mutant astrocytoma and an IDH1-mutant oligodendroglioma that represents defined evolutionary stages of chemotherapy-induced hypermutation. The PDCs retain tumor subtype defining features over time as well as classic hallmarks of cancer, including anchorage independent growth and cell immortality. The integrated phylogenies composed of PDCs,single-cell-derived PDCs, patient-derived xenografts, and corresponding spatiotemporal tumor tissue samples also provide new insight into the clonality, evolutionary pattern, and immense mutational load of hypermutated IDH mutant gliomas.
Study
EGAS00001003992
-
Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia
Study
EGAS00001004407
-
FOXM1 is a biomarker of resistance to PI3Kα inhibition in ER+ breast cancer that is detectable using metabolic imaging (RNA-seq data)
Study
EGAS00001004452
-
Clinical relevance of somatic copy-number alterations in plasma circulating tumor DNA from advanced EGFR-mutated NSCLC patients treated with osimertinib
Study
EGAS00001004539
-
TCR β-chain repertoire characterization of regulatory and conventional T cells in breast tumors from breast cancer patients.
Study
EGAS00001004671
-
Assessment of cannabidiol and Δ9-tetrahydrocannabiol in mouse models of medulloblastoma
Study
EGAS00001004963
-
Single-cell profiling of neoantigen-specific T cells in lung cancers treated with neoadjuvant PD-1 blockade
Study
EGAS00001005343
-
RNA-sequencing of tumors from 45 patients with recurrent or metastatic gastric cancer treated with immune checkpoint inhibitors
Study
EGAS00001005588
-
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
Study
EGAS00001005676
-
Mult-omics Palbociclib Resistance Study in HR+/HER2– Metastatic Breast Cancer
Study
EGAS00001005736
-
Genome-wide cell-free DNA termini in patients with cancer
Study
EGAS00001005738
-
Genome-wide cell-free DNA termini in patients with cancer
Study
EGAS00001005747
-
Accumulation of copy number alterations and clinical progression across advanced prostate cancer
Study
EGAS00001006251
-
early-stage ESCC sequencing study
Study
EGAS00001006126
-
Genome-wide cell-free DNA termini in patients with cancer
Study
EGAS00001006142
-
Intratumoral Heterogeneity and Clonal Evolution Induced by HPV Integration.
Study
EGAS00001006652
-
RNA-seq of DF149 cells – a patient-derived xenograft model of ascites-derived, homologous recombination repair-proficient, high-grade serous ovarian carcinoma – cultured in vitro and isolated after 8 hours treatment with DMSO control (3 x biological replicates) and 2.5 µM CBL0137 (3 x biological replicates)
Study
EGAS00001006662
-
Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification (H021)
Study
EGAS00001006706
-
Non-muscle Invasive Bladder Cancer Molecular Subtypes Predict Differential Response to Intravesical Bacillus Calmette-Guérin
Study
EGAS00001006879
-
Multi-omic and functional analysis for classification and treatment of sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions(H021/INF)
Study
EGAS00001006939
-
ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA
Study
EGAS00001007077
-
Implementation of pediatric precision oncology into clinical practice: The individualized Therapies for Children with cancer program “iTHER”
Study
EGAS00001007099
-
Single-cell decoding of drug induced transcriptomic reprogramming in triple negative breast cancers
Study
EGAS00001007242
-
Clinical outcomes and immune correlates of response to nivolumab plus chemoradiotherapy in women with locally-advanced cervical cancer – NiCOL study
Study
EGAS00001007297
-
Pediatric Patient-Derived-Xenograft development in MAPPYACTS – international pediatric cancer precision medicine trial in relapsed and refractory tumors
Study
EGAS00001007327